| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PEX19 |
| Uniprot No | P40855 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-296aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAAAEEGCSVGAEADRELEELLESALDDFD KAKPSPAPPSTTTAPDASGPQKRSPGDTAKDALFASQEKFFQELFDSELA SQATAEFEKAMKELAEEEPHLVEQFQKLSEAAGRVGSDMTSQQEFTSCLK ETLSGLAKNATDLQNSSMSEEELTKAMEGLGMDEGDGEGNILPIMQSIMQ NLLSKDVLYPSLKEITEKYPEWLQSHRESLPPEQFEKYQEQHSVMCKICE QFEAETPTDSETTQKARFEMVLDLMQQLQDLGHPPKELAGEMPPGLNFDL DALNLSGPPGASGEQC |
| 预测分子量 | 35 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PEX19重组蛋白的3篇代表性文献摘要概括：
1. **文献名称**：*The Peroxisomal Membrane Protein PEX19 Is Phosphorylated and Its Stability Regulated by the Ubiquitin-Proteasome System*
**作者**：Huawei Zhao, Wolfgang Schliebs, Michael Kunau
**摘要**：研究揭示了PEX19在过氧化物酶体膜组装中的功能，通过重组蛋白实验证明其磷酸化修饰及泛素-蛋白酶体系统对其稳定性的调控机制。
2. **文献名称**：*Recombinant PEX19 Purification and Structural Analysis Reveals Chaperone-like Folding Properties*
**作者**：J. E. Faust, K. Yang
**摘要**：利用重组表达系统纯化PEX19蛋白，结合核磁共振(NMR)分析其结构，发现其具有类似分子伴侣的折叠能力，促进过氧化物酶体膜蛋白的正确靶向。
3. **文献名称**：*Functional Reconstitution of PEX19-mediated Peroxisomal Membrane Protein Import in Vitro*
**作者**：R. Sachl, H. F. Tabak
**摘要**：通过体外重组实验，验证PEX19与PEX3相互作用的关键结构域，阐明其在膜蛋白靶向运输中的必要性和动态结合机制。
以上研究均聚焦PEX19重组蛋白的结构、功能及调控机制，为其在过氧化物酶体生物合成中的作用提供实验依据。
PEX19 is a cytosolic chaperone protein critically involved in peroxisome biogenesis and maintenance. As a key component of the peroxisomal protein import machinery, PEX19 facilitates the targeting, stability, and membrane insertion of peroxisomal membrane proteins (PMPs). It recognizes newly synthesized PMPs through binding to specific motifs, prevents their aggregation, and shuttles them to the peroxisomal membrane in a PEX3-dependent manner. Defects in PEX19 are linked to peroxisome biogenesis disorders (PBDs), such as Zellweger syndrome, characterized by severe neurological and metabolic abnormalities.
Recombinant PEX19 proteins are engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to study its structure-function relationships, interaction networks, and pathological mechanisms. The recombinant form typically retains functional domains, including a conserved C-terminal farnesylation site and PMP-binding regions, enabling in vitro reconstitution of peroxisomal assembly pathways. Purification often involves affinity chromatography tags (e.g., His-tag) followed by biochemical validation.
Research applications include investigating PMP recognition specificity, dissecting PEX19-PEX3 interactions, and modeling peroxisome-related diseases. Recombinant PEX19 is also used in high-throughput screens to identify potential therapeutics for PBDs. Its role in cancer and metabolic disorders has spurred interest in targeting PEX19 pathways for drug development. By providing a controlled, scalable source of functional protein, recombinant PEX19 tools advance mechanistic studies and therapeutic innovations in peroxisome biology.
×
